Anixa Biosciences Inc (NASDAQ: ANIX)’s stock price has soared by 23.19 in relation to previous closing price of 2.76. Nevertheless, the company has seen a gain of 17.65% in its stock price over the last five trading days. prnewswire.com reported 2025-06-09 that SAN JOSE, Calif., June 9, 2025 /PRNewswire/ — Anixa Biosciences, Inc. (“Anixa” or the “Company”) (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Dr. Robert Wenham, Chair of the Gynecologic Oncology Program at Moffitt Cancer Center, and the principal investigator of the Phase 1 clinical trial of Anixa’s ovarian cancer CAR-T immunotherapy, will present an e-poster at the European Society for Medical Oncology (“ESMO”) Gynaecological Cancers Congress 2025, to be held on June 19-21, 2025 in Vienna, Austria.
Is It Worth Investing in Anixa Biosciences Inc (NASDAQ: ANIX) Right Now?
ANIX has 36-month beta value of 0.33. Analysts have mixed views on the stock, with 1 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ANIX is 30.50M, and currently, short sellers hold a 1.24% ratio of that float. The average trading volume of ANIX on June 10, 2025 was 56.17K shares.
ANIX’s Market Performance
ANIX stock saw an increase of 17.65% in the past week, with a monthly gain of 29.28% and a quarterly increase of 29.28%. The volatility ratio for the week is 10.95%, and the volatility levels for the last 30 days are 5.88% for Anixa Biosciences Inc (ANIX). The simple moving average for the past 20 days is 26.54% for ANIX’s stock, with a 15.05% simple moving average for the past 200 days.
Analysts’ Opinion of ANIX
Many brokerage firms have already submitted their reports for ANIX stocks, with Maxim Group repeating the rating for ANIX by listing it as a “Buy.” The predicted price for ANIX in the upcoming period, according to Maxim Group is $10 based on the research report published on March 21, 2025 of the current year 2025.
Chardan Capital Markets, on the other hand, stated in their research note that they expect to see ANIX reach a price target of $8. The rating they have provided for ANIX stocks is “Buy” according to the report published on December 23rd, 2022.
H.C. Wainwright gave a rating of “Buy” to ANIX, setting the target price at $11 in the report published on April 12th of the previous year.
ANIX Trading at 26.16% from the 50-Day Moving Average
After a stumble in the market that brought ANIX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -19.05% of loss for the given period.
#####
#####
Insider Trading
Reports are indicating that there were more than several insider trading activities at ANIX starting from KUMAR AMIT, who purchase 10,000 shares at the price of $2.85 back on Jun 04 ’25. After this action, KUMAR AMIT now owns 569,925 shares of Anixa Biosciences Inc, valued at $28,500 using the latest closing price.
Baskies Arnold M, the Director of Anixa Biosciences Inc, purchase 5,000 shares at $2.82 during a trade that took place back on Jan 28 ’25, which means that Baskies Arnold M is holding 120,000 shares at $14,100 based on the most recent closing price.
Stock Fundamentals for ANIX
The total capital return value is set at -0.8. Equity return is now at value -61.14, with -58.71 for asset returns.
Based on Anixa Biosciences Inc (ANIX), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -34.48.
Currently, EBITDA for the company is -12.66 million with net debt to EBITDA at 0.06. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.89.
Conclusion
To put it simply, Anixa Biosciences Inc (ANIX) has had a better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
